Interestingly, comparing the immune gene expression profile of pretreatment samples from patients with a high and low top 1% clonal space, several immune gene signatures such as Interferon gamma and IL2 were differentially expressed, suggesting that this biomarker can be used to predict response to therapy and to evaluate tumor immunogenicity [94]. The gene discussed is IL2; the disease is neoplasm.